Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)

Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)

Abstract Background and Objective GP2015 is an etanercept biosimilar. Equivalent efficacy and comparable safety of GP2015 to reference etanercept (ref-ETN) was demonstrated in two phase III studies, one in patients with moderate-to-severe chronic plaque-type psoriasis (PsO; EGALITY study) and the ot...

Full description

Saved in:
Bibliographic Details
Main Authors: Diamant Thaçi, Sascha Gerdes, Hendrik Schulze-Koops, Yannick Allanore, Arthur Kavanaugh, Charlotte Both, Sreekanth Gattu, Sohaib Hachaichi, Marco Matucci-Cerinic
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Drugs in R&D
Online Access:https://doi.org/10.1007/s40268-025-00507-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40268-025-00507-8

Similar Items